Huaan Hang Seng Biotech ETF(159102.SZ)

Hong Kong customs seizes 14,080 smuggled slimming jabs bound for Macau

Hong Kong customs seized over 14,000 smuggled weight-loss injections valued at approximately HK$56 million (US$7.2 million) destined for Macau. The injections, labeled "Mounjaro" by Japan's Tanabe Pharma, were found on a river trade vessel along with other smuggled goods. Customs is investigating the authenticity of the products and potential syndicate operations, as these slimming jabs require a prescription in Hong Kong. Concerns have been raised about the illegal sale of such medications online and their associated health risks.

Pakistan becomes latest Asian country to introduce checks for deadly Nipah virus

Pakistan has implemented enhanced screening for the Nipah virus at its borders following confirmed cases in India. Other Asian countries, including Thailand, Singapore, and Vietnam, have also increased health controls. The Nipah virus, which has a high mortality rate but is not easily transmitted, requires travelers to undergo thermal screening and provide transit history. The World Health Organization classifies Nipah as a priority pathogen, with a case fatality rate of 40% to 75%.

IIP growth surges to 7.8%, giving Budget room to tackle debt, boost employment

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

23:51 ET Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

Akeso, Inc.announced that its drug ivonescimab has been included in FirstWord Pharma's list "The Drugs That Will Shape 2026." This list highlights 20 key drugs expected to transform the pharmaceutical industry. Ivonescimab is notable as the only drug from a Chinese innovative pharmaceutical company. The list also features other significant therapies from major pharmaceutical companies. Akeso is committed to addressing unmet clinical needs and advancing innovative medicines globally, with a focus on autoimmune and neurological disorders.